(R)-Lansoprazole

filler

Catalog No. Size 价格库存数量
S3680-2 Solid 2 mg ¥80
售罄
不可用
S3680-10 Solid 10 mg ¥240
售罄
不可用

详情描述

Dexlansoprazole, also known as Dexilant and TAK-390MR, is a proton pump inhibitor that employs a novel release formulation that prolongs its absorption. Dexlansoprazole is used to treat non-erosivegastroesophageal reflux disease.

Product information

CAS Number: 138530-94-6

Molecular Weight: 369.36

Formula: C16H14F3N3O2S

Synonym:

Dexlansoprazole

Kapidex

Dexilant

Chemical Name: 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole

Smiles: CC1=C(C=CN=C1C[S@@](=O)C1NC2=CC=CC=C2N=1)OCC(F)(F)F

InChiKey: MJIHNNLFOKEZEW-RUZDIDTESA-N

InChi: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (270.74 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

The plasma concentrations of (R)-lansoprazole are remarkably higher in all three CYP2C19 genotype groups than those of the corresponding (S)-enantiomer. The AUC0-∞ Cmax and elimination half-life of (R)-lansoprazole are significantly greater and longer, respectively, than those of the (S)-enantiomer for all three genotype groups.

References:

  1. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.
  2. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.
  3. M Miura, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8.

Products are for research use only. Not for human use.

相似产品

Recently viewed